Acacia Pharma Group plc Acacia Pharma Announces Chief Financial Officer Gary Gemignani Is To Leave The Company

 
TIDMACPH 
 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

Cambridge, UK and Indianapolis, US -- 23 March 2022: Acacia Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces that its Chief Financial Officer (CFO) Gary Gemignani is to leave the Company to pursue another opportunity and will work with the Company to transition his responsibilities in advance of a successor being named.

Contacts

 
Acacia Pharma Group plc                          International Media 
 Mike Bolinder, CEO                               Frazer Hall, Mark Swallow, David 
 [phone] / [phone]                Dible 
 mailto:[e-mail] [e-mail]   MEDiSTRAVA Consulting 
                                                  [phone] 
                                                  mailto:[e-mail] 
                                                  [e-mail] 
-----------------------------------------------  ------------------------------------ 
US Investors                                     Media in Belgium and the Netherlands 
 LifeSci Advisors                                 Chris Van Raemdonck 
 Irina Koffler                                    [phone] 
 [phone]                                  mailto:[e-mail] 
 mailto:[e-mail]              [e-mail] 
 [e-mail] 
-----------------------------------------------  ------------------------------------ 
 

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Barhemsys(R) (amisulpride) injection is a selective dopamine (D(2) and D(3) ) receptor antagonist approved and available in the US for the treatment and prevention of postoperative nausea & vomiting (PONV) in adult patients.

Please see full prescribing information, including Important Safety Information, at https://www.globenewswire.com/Tracker?data=p2OFDDfA0d5Udn1GNR7P-lXLJJBmCLi_FzkXEK7xASdWhs4bCnMfJKJlIxc6X7P04EBoi2GkRD-V1tyKpEQnPLOnSW5LboEfk1b3HIxlwuHxgYItjYAvcHpOEwJMfNsJUIrh8cCXSxumnXyy7BeD8sKCnqjAZPXvNp0N470fg5yFV4UDzAejDyXf0V08unFhB9C-kj-jrc1p6HbqxEOqVGsT-eB10vD44ycxAfiX0bU= www.BARHEMSYS.com.

Byfavo(R) (remimazolam) for injection, is an IV benzodiazepine sedative approved and available in the US for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Byfavo is in-licensed from Paion UK Limited for the US market.

Please see full prescribing information, including Important Safety Information and Boxed Warning, at https://www.globenewswire.com/Tracker?data=p2OFDDfA0d5Udn1GNR7P-ko2JK2uqu05Bb62BrkEUSnGfwHxtjN7q6ORPry1Xqt2MeXR9nCGZi7qJ46Sl9rpb5UZXzJfA3XxF2LVt1wjPAofaDMKxUBl4HhnaiQH8Lz13aKLkw3PHL5Eq0iqEip_ujuLiqa0VU3y6RsN4MrFBgsDWmeEuAHdIiPxAmBYkUECZ3pSmPbOV98URlNzte-im3mD3G9IytCO4A_uuPjqglY= www.BYFAVO.com.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

This release is intended for investors and media only.

https://www.globenewswire.com/Tracker?data=p2OFDDfA0d5Udn1GNR7P-u8AT8objLFLhkzY0dooJeadoAen64vIfC9D8aIFtkAiADOBoKihDoFohMJszM4wQC-i8VOwYz9b820FrgJOiSFk0zdN0OsqA8AXLj75Uj9bWMHblxeH8Y7i29b_z26vubwdcjUvWpoZ2iXwGEPlOKnux6O3X_N2VVEi1NEb9H0Bzna8bPbQgnOG5tB3TYc5rCtGypz0PEnsU5PtTwDfTaDw0YBcybxgjltei3CAYPQc_EYi837mYct9yvemGIZI5A== www.acaciapharma.com

Forward looking statement

This announcement includes forward-looking statements, which are based on current expectations and projections about future events. These statements may include, without limitation, any statements preceded by, followed by or including words such as "believe", "expect", "intend", "may", "plan", "will", "should", "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements may and often do differ materially from actual results. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and investments, including, among other things, the development of its business, trends in its operating industry, and future capital expenditures and acquisitions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's business, results of operations, financial position, prospectus, growth or strategies and the industry in which it operates. Save as required by law or applicable regulation, the Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. Forward-looking statements speak only as of the date they are made.

(END) Dow Jones Newswires

March 23, 2022 02:10 ET (06:10 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.